Antibiotic synergy and antagonism

Medical Clinics of North America

Volumn 84, Issue 6, 2000, Pages 1391-1406

  Acar, Jacques F ^b  

^a SAINT JOSEPH HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBENICILLIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CLOXACILLIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MECILLINAM; NAFCILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; STREPTOGRAMIN; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TRIMETHOPRIM; UNINDEXED DRUG; UREIDOPENICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG UPTAKE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0033658368     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70294-7     Document Type: Article

References (62)

1. Synergistic activity of trimethoprim-sulfamethoxazole on gram-negative bacilli: Observations in vitro and in vivo
2. Combinations of antibiotics in urinary tract infections
3. Comparison of three different regimens in the treatment of acute brucellosis: A multicenter multinational study
4. In vivo activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus
5. Antibiotic synergy in experimental infection with Pseudomonas: II. The effect of carbenicillin, cephalothin or cephanone combined with tobramycin or gentamicin
6. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin
7. Synergism, killing, and antimicrobial susceptibility of group A and B streptococci
8. Synergy of mecillinam (FL 1060) with penicillins and cephalosporins against Proteus and Klebsiella, with observations on combinations with other antibiotics and against other bacterial species
9. Methods for testing antimicrobic combinations
10. Correlations between methods for measurement of synergy
11. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli
12. In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semi-synthetic streptogramin: RP 59500
13. Synergism between trimethoprim and sulfamethoxazole
14. Beta-lactamase inhibitors from laboratory to clinic
15. Trimethoprim: A sulfonamide potentiator
16. Comparison of different β-lactam-glycopeptidegentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium
17. Cellophane transfer: Application to the study of activity of combination of antibiotics
18. Inhibition of protein synthesis by streptogramins and related antibiotics
19. Haemophilus endocarditis: Report of 42 cases in adults and review
20. Regression line analysis of the synergistic effect for the combination of trimethoprim-sulfamethoxazole
21. Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents
22. Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to β-lactam antibiotics
23. Ciprofloxacin in combination with other antimicrobials
24. Antimicrobial combinations
25. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
26. Comparative inhibition of β-lactamases by novel β-lactam compounds
27. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates
28. Methods of testing combined antibiotic bactericidal action and the significance of the results
29. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides
30. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin
31. Comparative evaluation of a new β-lactamase inhibitor, YTR 830, combined with different β-lactam antibiotics against bacteria harboring known β-lactamases
32. Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some β-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam)
33. Synergism and antagonism in double β-lactam antibiotic combinations
34. Studies on antibiotic synergism and antagonism: A scheme of combined antibiotic action
35. The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro
36. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens
37. The clinical use of combinations of antibiotics in patients predisposed to severe infection
38. Synergistic combinations of antibiotics in gram-negative bacillary infections
39. Penicillin- and cephalosporin-resistant Streptococcus pneumoniae: Emerging treatment for an emerging problem
40. Aminoglycoside inactivating enzyme: An explanation for resistance to penicillin-aminoglycoside synergism in enterococci
41. First characterization of inhibitor-resistant TEM (IRT) β-lactamases in Klebsiella pneumoniae strains
42. The fractional maximal effect method: A new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions
43. Technique for determining the bactericidal effect of drug combinations
44. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis
45. Antimicrobial combinations
46. Current management of bacterial meningitis in infants and children
47. Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin
48. 14C-labeled streptomycin by enterococci
49. Prevalence of high level resistance to aminoglycosides in clinical isolates of enterococci
50. Antibiotic combinations: The clinical relevance of synergy and antagonism
51. Is monotherapy for febrile neutropenia still a viable alternative?
52. Synergistic penicillin combinations for treatment of human urinary tract infections
53. In vivo antagonism between gentamicin and chloramphenicol in neutropenic mice
54. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats
55. Antibiotic combinations in the treatment of experimental Staphylococcus aureus infection
56. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo
57. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus
58. Combination of antibiotics in severe pneumonias due to gram-negative bacilli
59. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural element that regulate expression - A review
60. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa
61. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms: American Heart Association
62. Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis